

1 **Title: Pivotal role of early coronary microvascular dysfunction in Takotsubo Syndrome**

2 Short title: Coronary flow retardation is central to Takotsubo Syndrome

3

4 Gao Jing Ong MBChB PhD ^{1,2,3}

5 Farnaz Jalili ³

6 Gnanadevan Mahadavan MBBS PhD ^{1,3}

7 John D Horowitz MBBS PhD ^{2,3}

8

9 ¹ Cardiology Unit, Central Adelaide Local Health Network, South Australia 5000, Australia.

10 ² Cardiovascular Pathophysiology and Therapeutics Group, Basil Hetzel Institute for
11 Translational Health Research, The Queen Elizabeth Hospital, Woodville South, South
12 Australia 5011, Australia.

13 ³ University of Adelaide, Adelaide, South Australia 5000, Australia.

14

15 Address and contact details for Correspondence: John D Horowitz, Cardiology Research
16 Laboratory, Basil Hetzel Institute, University of Adelaide, Adelaide, SA, Australia.

17 Email: john.horowitz@adelaide.edu.au

18 Contact number: +61 457827046

19

20 Total word count: 5738

21 **Abstract**

22 Background: Takotsubo Syndrome (TTS) generally presents like a form of acute coronary
23 syndrome, with variable extents of coronary flow retardation and concomitant release of
24 markers from damaged endothelial glycocalyx (eGC). Whilst systemic hypotension often
25 develops early, there is also rapid emergence and slow resolution of left ventricular (LV)
26 dysfunction. It remains uncertain whether these hypotensive and LV functional
27 complications reflect severity of early coronary vasculitis.

28 Methods: 284 patients admitted to 3 South Australian hospitals from May 2008 to May
29 2021 with a diagnosis of TTS were evaluated. Coronary flow velocity was measured using
30 the corrected TIMI frame count. Putative correlations between extent of acute coronary
31 flow retardation and that of acute impairment of LV systolic function, as measured on global
32 longitudinal strain (GLS: primary hypothesis), were determined. Other parameters of acute
33 disturbance of homeostasis, including extent of eGC shedding and of myocardial edema,
34 and residual impairment in GLS and quality of life at 3-months' follow-up, were correlated
35 with extent of flow retardation. We also evaluated correlates of extent of acute systemic
36 hypotension. Results were analysed via univariate followed by multivariate analyses.

37 Results: The patients studied exhibited mild coronary flow retardation relative to previously
38 described norms at early angiography. On univariate analyses, corrected TIMI frame count
39 correlated with extent of acute impairment of GLS ($r=0.31$, $p=0.003$) and this association
40 persisted on backwards stepwise multiple logistic regression ($\beta=0.52$, $p=0.03$). Flow
41 retardation also correlated with preservation of renal function ($\beta=0.50$, $p=0.02$), but tended
42 to vary inversely with C-reactive protein (CRP) concentrations ($\beta=-0.44$, $p=0.06$). There were
43 no significant associations between acute TIMI frame count and other acute or 3-months'

44 parameters. Neither TIMI frame count nor acute GLS predicted minimal systolic blood
45 pressure.

46 Conclusions: The data demonstrated a strong association between extent of early coronary
47 flow reduction in TTS and that of LV functional impairment, thus establishing some
48 commonality of causation of the coronary and acute myocardial manifestations of TTS.
49 However, neither extent of coronary vasculitis nor that of acute LV systolic dysfunction
50 predict acute hypotensive changes in TTS.

51

52 Key words: Takotsubo Syndrome, Coronary flow retardation, Global longitudinal strain,
53 Myocardial edema

54

55 **Clinical Perspective**

56 What is new?

57 • We have shown for the first time, that the extent of acute coronary flow retardation
58 in Takotsubo Syndrome (TTS) predicts that of early impairment in left ventricular (LV)
59 systolic function.

60 • However, severity of acute hypotension is independent of both coronary flow
61 reduction and LV functional impairment.

62 What are the clinical implications?

63 • These results confirm that the initial pathophysiology of TTS is that of coronary
64 vasculitis, and that the severity of this vasculitis predicts the extent of LV dysfunction.

65 • Therefore, future therapeutic investigations in TTS should focus on early intervention
66 to limit coronary vasculitis.

67 • Hypotension/shock in acute TTS appear to have little to do with extents of acute
68 coronary vasculitis or of LV systolic dysfunction, and therefore theoretically, neither
69 coronary vasodilatation nor positive inotropic therapy is likely to ameliorate this
70 problem.

71

72 Introduction

73 Takotsubo Syndrome (TTS) is an acute inflammatory cardiac condition that is usually
74 characterized by an acute coronary syndrome (ACS)-like presentation, followed by a
75 congestive cardiac failure (CCF) aftermath(1). Like patients with acute myocardial infarction
76 (MI), TTS patients typically present with symptoms of chest discomfort and/or dyspnea, with
77 electrocardiographic (ECG) changes, and biochemical evidence of myocardial injury(1).
78 There is also acute evidence of segmental (typically apical) left ventricular (LV) systolic
79 dysfunction, which tends to resolve only partially within 3 months(2, 3), with associated
80 symptoms of dyspnea and lethargy(4).

81 The major clinical problem encountered during the acute phase of TTS is symptomatic
82 hypotension/shock, which is a marker of increased short-term mortality(5), even though it is
83 not closely related to extent of simultaneous LV systolic dysfunction(6), nor to impairment
84 of cardiac output(7).

85 Although TTS often occurs in the absence of stenoses in large epicardial coronary arteries,
86 there is evidence of acute regional myocardial ischemia(8, 9), with variable retardation of
87 epicardial coronary flow rates(10). These changes occur in parallel with ECG abnormalities
88 resembling those of evolving acute MI. These findings beg the question of: What precisely
89 causes the associated ischemia?

90 Pathological retardation of coronary flow rates [the “coronary slow flow
91 phenomenon”(CSFP)(11)] may occur as a component of reperfusion injury post MI(12), but
92 also as an infarct-independent form of acute-on-chronic small coronary artery disease(13).

93 We have recently demonstrated that this “acute on chronic CSFP” results from
94 microvascular spasm, with associated but reversible damage to the *endothelial glycocalyx*

95 (eGC), a carbohydrate-rich layer between endothelial cells and the vascular lumen(14).
96 Damage to the eGC results in (i) impairment of vascular rheology(15) and hence
97 theoretically increased microvascular resistance, (ii) increased expression of thioredoxin-
98 interacting protein (TXNIP), which in turn activates the NLRP3 inflammasome(16), and (iii)
99 increased vascular permeability(17), facilitating development of tissue edema, and
100 extravasation of leukocytes. *All of these* have been described in the acute phases of TTS(18-
101 20).

102 TTS therefore appears to present as an acute coronary “vasculitis”, and then a subsequent
103 and prolonged myocarditis(21). If this is the case, it is possible, although currently unproven,
104 that the extent of acute coronary vasculitis is a determinant of both severity of subsequent
105 myocarditis (and associated LV systolic dysfunction) and of the risk of severe acute
106 hypotension.

107 In the current study, utilising a large and detailed database of TTS patients, we sought to
108 test the hypotheses that:

109 (1) Vasculitis predicts myocarditis

110 (a) The extent of acute coronary flow retardation correlates directly with that of
111 acute LV systolic dysfunction, as measured by global longitudinal strain (GLS) on
112 echocardiography (primary hypothesis). Echocardiographic left ventricular
113 ejection fraction (LVEF), a less precise marker of LV systolic function, was also
114 assessed.

115 (b) The extent of acute coronary flow retardation correlates directly with other
116 acute markers of:

- 117 i. Biochemical evidence, and clinical and radiological consequences, of eGC
118 damage, namely:
- 119 a. Minimal systolic BP during the hospitalization
120 b. Myocardial edema score on acute cardiac magnetic resonance
121 imaging (CMR)
122 c. Plasma concentration of the eGC component syndecan-1 (SD-1)
- 123 ii. Markers of extent of myocardial injury:
- 124 a. Peak plasma concentration of Troponin-T
125 b. Peak plasma concentration of NT-proBNP
126 c. Plasma concentration of the catecholamine metabolite
127 normetanephrine
- 128 iii. Platelet NO responsiveness, which is typically impaired proportionally to
129 extent of redox stress(22).
- 130 (c) The extent of early coronary flow retardation predicts residual impairment 3
131 months post TTS:
- 132 i. GLS on echocardiography
133 ii. Quality of life scores as measured using the SF-36 questionnaire, with a
134 particular focus on the physical component scores (SF36-PCS)

135 (2) Vasculitis predicts hypotension/shock independent of myocarditis

136 We reasoned that if the major mechanism responsible for development of acute
137 hypotension was increased vascular permeability, this would imply that extent of
138 hypotension might be independent of that of LV systolic dysfunction.

139 The results of these two types of analyses establish that (i) the extent of coronary flow
140 retardation parallels that of acute impairment of LV systolic function in TTS patients, and (ii)

141 that extent of acute hypotension is independent, both of impairment of LV systolic function

142 and of coronary flow retardation.

143

144 **Methods**

145 *Patient selection and baseline characteristics*

146 This study was approved by the local human research ethics committee. Data from
147 consecutive TTS patients (n=400) who presented to 3 tertiary hospitals in South Australia
148 between May 2008 to May 2021 were assessed. Of these, patients who had early invasive
149 coronary angiography, with adequate image quality for accurate image interpretation and
150 frame counting were included in the analysis (n=284). A study flow chart summary is shown
151 in Figure 1. The diagnosis of TTS was made according to the InterTAK diagnostic criteria(1).
152 Baseline demographics, including age, sex and comorbidities including diabetes and smoking
153 status were recorded. Data regarding predominant site of left ventricular (LV) hypokinesia
154 and known precipitants of TTS were also recorded.

155 Patients were routinely admitted to the coronary care or intensive care units, where blood
156 pressures (BP) were recorded hourly, and ECGs performed at least daily. Venesection was
157 performed routinely for measurement of hemoglobin (Hb), C-reactive protein (CRP) and
158 estimated glomerular filtration rate (eGFR) from plasma creatinine concentrations, as well
159 as plasma NT-proBNP, Troponin-T, and normetaphrine concentrations. In subsets of patients,
160 the following were also measured during the first 24 hours post onset of symptoms, in all
161 cases related to testing of specific hypotheses concerning the pathogenesis of TTS(18, 23):

- 162 (1) Extent of damage to the eGC, measured using plasma SD-1 concentrations (n=38)
- 163 (2) Platelet nitric oxide (NO) responsiveness, measured by the extent of inhibition of
164 platelet aggregation with the NO donor, sodium nitroprusside (SNP) (n=48)

165 Plasma SD-1 concentrations were measured using immunoassay (sCD138 ELISA Kit, Diaclone
166 Research, France). The extent of inhibition of ADP-induced platelet aggregation with SNP
167 was measured using a dual channel impedance aggregometer (Model 560, Chrono-Log,
168 Havertown, PA, USA), as previously described(24).

169

170 *Invasive coronary angiography*

171 Coronary angiography was generally performed on an emergency basis. The time from
172 hospital presentation to invasive coronary angiography was recorded. Coronary angiography
173 was performed with standard sequences of angiographic views, and cine images were
174 acquired at various frame rates, ranging between 10 frames per second and 30 frames per
175 second. Coronary artery flow velocity was assessed based on TIMI Frame Count (TFC), a
176 method previously described by Gibson et al(25). TFC is the number of cineframes required
177 for contrast to first reach a standardized distal coronary landmark in the coronary vessel of
178 interest. The first frame used in TFC counting is the first frame where contrast dye fully
179 enters the coronary artery, and for the left anterior descending (LAD) coronary artery for
180 example, the final frame is when the contrast dye reaches the most distal visible LAD
181 bifurcation. As the length of the LAD is typically greater than the left circumflex (LCx) and
182 the right coronary (RCA) arteries, a correction ratio of 1:1.7 is used to standardize the TFC in
183 LAD and non-LAD vessels(25).

184 TFCs were measured by both FJ and GO with mean inter-observer variability of 9% of TFC.

185 Due to the variability in image acquisition rate, the number of frame counts was adjusted to
186 the equivalence of 30 frames per second(25).

187

188 *Echocardiography*

189 Transthoracic echocardiography was performed in all patients at acute presentation (usually
190 <48 hours of presentation) and again at 3 months follow-up. Standard apical two-chamber,
191 three-chamber, and four-chamber views were obtained with special attention to LV
192 endocardial definition, at a frame rate of at least 50 frames per second. Global longitudinal
193 strain (GLS) was analysed using speckle-tracking software (Philips or GE) specific to each
194 manufacturer. The endocardial border was manually traced, and region of interest was
195 drawn to include the entire myocardium in all cases. Images were only accepted for analysis
196 when segments approved for speckle analysis were tracked reliably. In addition, left
197 ventricular ejection fraction (LVEF) was also measured using echocardiography, and was
198 calculated using the biplane method.

199

200 *Cardiac magnetic resonance (CMR) imaging*

201 CMR was performed in patients without any contraindications to this procedure during their
202 initial hospital admission, on a 1.5T Philips MRI system, with a five-channel phased- array
203 coil and electrocardiographic gating. T2-weighted-Black-Blood images were analysed to
204 determine the extent of myocardial inflammation, utilising certified MRI evaluation
205 software [OsiriX Lite (<http://www.osirix-viewer.com/>)]. In each patient, short axis views of
206 the left ventricle were obtained at the apex, mid and base, and the endocardial and
207 epicardial contours were traced manually in all 3 levels. In order to provide a measure of
208 total LV edema, we utilized methodology previously developed by Neil et al(26): Mean

209 signal intensity (SI) score was determined for each short-axis slice, and results were
210 expressed relative to the SI score of their spleen, giving a SI ratio (or a “T2WSI score”).

211

212 *Follow up*

213 Patients were followed up 3 months after the acute TTS attack, with LV systolic function
214 measured by GLS, and quality of life assessed using the SF-36 Questionnaire with a
215 particular focus on the physical component scores (SF36-PCS), both included in the analysis.

216

217 *Statistical analyses*

218 To test the central hypothesis that extent of coronary microvascular dysfunction during
219 acute TTS is directly associated with the extent of myocardial dysfunction, correlations were
220 sought between TFC on invasive coronary angiography with GLS on echocardiography.
221 Correlation analyses were performed by Pearson’s or Spearman’s correlation coefficients
222 as appropriate. Correlations were also sought for the secondary measures mentioned above
223 and listed in Figure 1. Associations between TFC and patient demographics were also sought
224 with unpaired t-test and Wilcoxon-Mann-Whitney test as appropriate. Subsequently, those
225 univariate parameters with a p-value ≤ 0.10 were included in a multivariate backwards
226 stepwise multiple logistic regression analysis to identify multivariate correlates of TFC.

227 In order to test the subsidiary hypothesis that extent of acute hypotension is independent of
228 extent of impairment in GLS, we performed univariate correlations of minimal systolic BP
229 with GLS, followed by backwards stepwise multiple logistic regression analysis, utilizing
230 minimal systolic BP as the dependent variable, and including age, pre-existing diagnosis of

231 hypertension, average (LAD-corrected) TFC, acute GLS, and peaked plasma NT-proBNP and
232 Troponin-T concentrations as potential correlates.

233 Data are presented as mean \pm SD or median (inter-quartile range) as appropriate, and the
234 limit of statistical significance was set at $p < 0.05$.

235 **Results**

236 *Patient characteristics and coronary angiography findings*

237 A total of 284 TTS patients were included in the analysis. Patient demographics are
238 summarized in Table 1. As expected, the majority of patients were older females, with few
239 conventional cardiovascular risk factors other than advanced age.

240 153 (53%) patients had an invasive coronary angiogram within the first 24 hours of their
241 presentation. Frame counts did not differ significantly between patients who had
242 angiography within 24 hours and those who did not.

243 The corrected TFC of the LAD correlated closely with the averaged TFC in other major
244 epicardial arteries ($r=0.83$, $p<0.0001$). Given the fact that TTS- associated myocardial edema
245 is seen not just in the hypokinetic left ventricular segments, but also throughout the
246 myocardium(26), the averaged (LAD-corrected) TFC of all coronary arteries was chosen as
247 the main dependent variable.

248 Median averaged (LAD-corrected) TFC of all 3 major coronary arteries was 33 frames (IQR
249 23.5-37.7), which is higher compared to previously reported data for healthy subjects (<21
250 frames)(25).

251 TFC did not significantly correlate with age ($p=0.23$), gender ($p=0.20$), smoking status ($p=0.9$)
252 or diabetes status ($p=0.50$). TFC also did not differ between apical and non-apical forms of
253 TTS ($p=0.21$). However, TFC was less elevated (median 30 vs 33 frames, $p=0.003$) in patients
254 with TTS precipitated by a physical trigger than in other subgroups ($p=0.03$).

255 Renal function was preserved in the majority of patients (median eGFR 67mL/min), and TFC
256 varied directly with eGFR on univariate correlation ($r=0.24$, $p<0.0001$)(Figure 2A). Plasma
257 CRP concentration correlated inversely with TFC ($r=-0.21$, $p=0.001$).

258

259 *Primary hypothesis: Does acute vasculitis predict subsequent myocarditis?*

260 (a) CSFP predicts extent of acute systolic functional impairment

261 The extent of coronary flow retardation correlated directly with that impairment of LV
262 systolic function on index echocardiography, as measured by GLS on univariate analysis
263 (Figure 3). However, this trend did not approach statistical significance when LVEF replaced
264 GLS ($p=0.27$).

265

266 (b) Other acute comparisons

267 Hypotension (systolic BP ≤ 90 mmHg) occurred in 37% of patients, with mean nadir of systolic
268 BP of 96mmHg in the studied population. Patients who had lower systolic BP tended to have
269 higher TFC ($r=-0.12$, $p=0.06$) (Figure 2B). There was however no significant correlation
270 between TFC and either T2WSI score on CMR ($p=0.75$) or plasma SD-1 concentration
271 ($p=0.33$).

272 Biochemical markers of extent of acute myocardial injury (peak plasma Troponin-T, NT-
273 proBNP, and normetanephrine concentrations) also did not correlate significantly with TFC
274 ($p=0.43$, $p=0.16$, and $p=0.37$ respectively).

275 In a subset of patients (n=48) where platelet NO responsiveness was measured, whilst there
276 was no statistically significant correlation between TFC and NO responsiveness, there was a
277 trend towards greater flow retardation(p=0.07) in patients with most pronounced
278 responsiveness to NO.

279

280 (c) Indices of late recovery

281 At 3 months' follow up, mean GLS was $-17.91\% \pm 3.14\%$, consistent with persistent but mild
282 LV systolic dysfunction in many patients. Similarly, quality of life scores were also mildly
283 impaired, with a mean SF36-PCS score of 56.1, as compared to the "normal" mean value of
284 65 for the female population aged 65-74 of the region of sampling(27). However, there was
285 no statistically significant correlation between extent of acute coronary flow retardation and
286 either GLS or quality of life scores at 3 months post-TTS (p=0.60 and p=0.67 respectively).

287

288 (d) Multivariate analysis

289 Acute GLS, TTS triggers, eGFR, lowest in-hospital systolic BP, and plasma CRP concentration
290 were included in a backwards stepwise multiple logistic regression analysis, where the
291 dependent variable was corrected TFC. The result of this multivariate analysis is summarized
292 in Table 3. Both acute GLS and eGFR were independent and direct correlates of TFC acutely
293 ($\beta=0.52$, p=0.03 and $\beta=0.50$, p=0.02 respectively). Surprisingly there was as trend (p=0.06)
294 for low CRP values to correspond to high acute TFC. Importantly, there was no correlation
295 between minimal systolic BP and TFC.

296

297 *Secondary hypothesis: Vasculitis predicts hypotension/shock independent of myocarditis*

298 The issue was approached by initial univariate correlation between TFC and minimal systolic
299 BP followed by multivariate analysis of correlates of minimal systolic BP. As previously
300 mentioned, TFC tended ($r=-0.12$, $p=0.06$) to be inversely correlated with minimal systolic BP
301 (Figure 2B). However, there was no significant univariate correlation between GLS and
302 minimal systolic BP (data not shown). On multivariate analysis, the absence of previous
303 systolic hypertension, and extent of acute Troponin-T rise were the only identified
304 significant correlates of minimal systolic BP ($\beta=0.33$, $p=0.002$ and $\beta=-0.27$, $p=0.01$
305 respectively).

306

307 **Discussion**

308 The precise pathophysiology of what is now usually named “Takotsubo Syndrome” remains
309 uncertain. The Japanese investigators who initially described the condition, including the
310 eponymous distortion of ventricular contraction, considered the ACS-like presentation and
311 suggested that the pathogenesis might be of multivessel coronary spasm(28). In retrospect,
312 this was surprising, because coronary artery spasm occurs very commonly in Japan(29), and
313 does not usually lead to myocardial necrosis(30). Conversely, a subsequent generation of
314 (largely European) investigators focused on the emergence, typically during the late
315 hospitalization period, of heart failure, and categorized the condition as a congestive
316 cardiomyopathy (TTC), a term which only recently has declined in use(31).

317 Very recently, we have proposed that *TTS begins as an acute coronary vasculitis, and*
318 *evolves into a myocarditis of variable severity and duration*(21). However, little has been
319 done to determine whether the putative second phase results from the first. In the current
320 study, our primary hypothesis was that extent of coronary flow retardation would predict
321 that of early GLS impairment. This proved to be the case. Thus, the rapid development of
322 segmental LV systolic dysfunction either directly reflects an identical stimulus, and/or
323 represents a predictable consequence of early coronary vasculitis.

324 Whilst injury to the vascular eGC may have contributed to impaired myocardial contractility
325 via vascular permeabilization(17), for example by facilitating monocyte and macrophage
326 transmigration(20), and increasing expression of the humoral pro-inflammatory protein
327 TXNIP(16), it is equally probable that flow retardation per se may have attenuated the Gregg
328 phenomenon(32), and thus impaired LV contractility.

329 Subsidiary investigations undertaken in this context sought correlations between TFC and a
330 number of biochemical parameters. The only significant correlations found were with CRP
331 concentrations, which were inversely related to TFC, and with eGFR, which was strongly and
332 directly related to TFC. The reasons underlying those findings are not clear-cut. As regards
333 eGFR, a possible explanation for this finding may be that hemodynamic changes in patients
334 with CKD induce physiological adjustments similar to those occurring in the “diving reflex”,
335 in that peripheral (catecholamine-induced) vasoconstriction predominates in patients with
336 CKD, leading to redistribution of blood flow to adequately perfuse the heart and the
337 brain(33). Indeed, there is also evidence of increased resting cerebral blood flow in patients
338 with CKD(34). The lack of an explanation for the findings regarding CRP correlations may
339 relate to the precipitation of TTS in a minority of patients by infections, but this remains
340 speculative at this stage. More extensive TFC prolongation tended to be associated ($p=0.07$)
341 with platelet hyper-responsiveness to NO, which has been implicated as being generated via
342 aberrant β -adrenoceptor stimulation and NO synthase activation(35, 36). This forms a basis
343 of peroxynitrite generation and thus incremental oxidative stress(19). This marginal
344 association is therefore not surprising.

345 Additionally, there was no correlation between extent of acute flow retardation and that of
346 LV systolic dysfunction and quality of life impairment after 3 months. Data from Dawson’s
347 group have revealed that both persistent myocardial energetic impairment and the
348 emergence of myocardial fibrosis are prominent late pathogenetic features in TTS(3):
349 presumably neither of these are closely related to extent of acute coronary vasculitis.

350 A secondary purpose of the current study was to provide additional understanding of the
351 factors responsible for the development of severe hypotension in the early stages of TTS.

352 We have previously shown that occurrence of severe hypotension is independent of acute
353 changes in pulmonary artery oxygen saturation (a marker of cardiac output)(7) and is
354 statistically related to fall in LVEF, but only weakly so(6). The current analysis showed that
355 minimal systolic blood pressure is significantly lower in patients without past histories of
356 hypertension, and also in patients with greater increases in plasma troponin-T
357 concentrations. The latter data are not unexpected, and unfortunately the
358 hypotension:troponin release nexus does not help elucidate cause vs effect. The current
359 quantitative and multivariate analysis does not provide significant clarification regarding
360 mechanism(s) of hypotension, which was independent both of TFC and of GLS.
361 Unfortunately, the current methodology did not permit us to measure extent of fluid
362 extravasation associated with coronary microvascular injury: this might have provided
363 significant mechanistic information. Nevertheless, the current data provide additional
364 evidence that extent of hypotension is not closely related to that of LV systolic dysfunction.
365 The issue of coronary vasculitis as a basis for subsequent myocardial dysfunction in TTS has
366 been appreciated in two previous studies, independent of our previous postulate of
367 sequential pathogenesis(21). In 2020, Montone et al. demonstrated in a cohort of 101 TTS
368 patients, that acute coronary flow retardation (TIMI-2 flow) was associated with an
369 increased risk of in-hospital acute heart failure(37). Sans-Rosello et al. evaluated changes in
370 coronary microvascular resistance in 166 TTS patients, and showed that increased
371 microvascular resistance predicted the occurrence of symptomatic heart failure (usually
372 mild) over subsequent 12 months(38). The importance of this study can now be seen as
373 providing an extension of our current acute/subacute findings for a period of at least 12
374 months(39). Finally, a very recent report(40) in a mouse model of transaortic constriction
375 demonstrated gradual development of LV apical hypokinesis, which was reversed by 2-4

376 weeks' treatment with the coronary vasodilator agent chromonar. Although it may be
377 hazardous to extrapolate from this experimental design to TTS, the findings might be
378 interpreted as additional evidence of a nexus between reversal of early coronary
379 vasoconstriction and of impaired systolic function in a "TTS-like" model.

380 There are several caveats to our study. Firstly, due to the retrospective design of our study,
381 our finding of directly related impairment of coronary flow and myocardial dysfunction
382 implies only association, rather than causation. It might be possible to test Koch's postulates
383 regarding causation by evaluating the impact of eGC-protecting agents, such as the matrix
384 metalloproteinase inhibitor doxycycline(41), the hydrogen sulphide donor N-
385 acetylcysteine(42), or even potentially sodium-glucose cotransporter-2 inhibitors (SGLT-2i)
386 such as empagliflozin(43).

387 Secondly, flow retardation as measured by TFC does not always represent microvascular
388 dysfunction, and other potential contributors such as coronary vascular ectasia(44), or
389 extramural compression of coronaries in association with diastolic dysfunction(45) may
390 need to be considered. Furthermore, myocardial edema quantitation utilized T2-weighted
391 signal intensity score measurement, as in our previous report(26):- it is possible that more
392 recently developed techniques such as T2-mapping sequences might have been more
393 precise(46). Finally, as the data on some secondary end points such as plasma SD-1
394 concentrations, myocardial edema score on CMR, and platelet NO responsiveness were only
395 available in small numbers of patients, these analyses were subject to Type 2 error.

396 In conclusion, we have shown for the first time, an acute association between coronary flow
397 retardation and myocardial systolic dysfunction in patients with TTS. Furthermore, the
398 extent of flow retardation is not a significant correlate of severity of hypotension. Thus, our

399 results establish a nexus between coronary vasculitis and myocarditis as a central
400 component of the pathogenesis of TTS, and suggest that limitation of coronary
401 microvascular dysfunction may represent an important early therapeutic target for patients
402 with TTS in the future.

403

404 **Acknowledgements**

405 We wish to acknowledge the contributions of Dr Yuliy Chirkov and Dr Ha Nguyen, who
406 performed the investigations of platelet physiology and of plasma SD-1 concentrations. We
407 also are grateful to the medical and nursing staff, as well as echocardiography and CMR
408 technicians at Lyell McEwin Hospital, Queen Elizabeth Hospital, and Royal Adelaide Hospitals.
409 Finally, we are very grateful to Ms Jeanette Stansborough for her substantial contributions
410 to patient recruitment and data entry.

411

412 **Sources of Funding**

413 GJO was partly supported by an Australian Postgraduate Scholarship from the University of
414 Adelaide.

415 FJ was supported by a short-term research scholarship from the Faculty of Medicine,
416 University of Adelaide.

417

418 **Disclosures**

419 All authors have no conflicts of interest to declare.

420 References

- 421 1. Ghadri J-R, Wittstein IS, Prasad A, Sharkey S, Dote K, Akashi YJ, et al. International Expert
422 Consensus Document on Takotsubo Syndrome (Part I): Clinical Characteristics, Diagnostic Criteria,
423 and Pathophysiology. *European heart journal*. 2018;39(22):2032-46.
- 424 2. Dawson DK, Neil CJ, Henning A, Cameron D, Jagpal B, Bruce M, et al. Tako-Tsubo
425 Cardiomyopathy: A Heart Stressed Out of Energy? *JACC: Cardiovascular Imaging*. 2015;8(8):985-7.
- 426 3. Scally C, Rudd A, Mezincescu A, Wilson H, Srivanasan J, Horgan G, et al. Persistent Long-Term
427 Structural, Functional, and Metabolic Changes After Stress-Induced (Takotsubo) Cardiomyopathy.
428 *Circulation*. 2018;137(10):1039-48.
- 429 4. Neil CJ, Nguyen TH, Singh K, Raman B, Stansborough J, Dawson D, et al. Relation of Delayed
430 Recovery of Myocardial Function After Takotsubo Cardiomyopathy to Subsequent Quality of Life.
431 *The American journal of cardiology*. 2015;115(8):1085-9.
- 432 5. Di Vece D, Citro R, Cammann Victoria L, Kato K, Gili S, Szawan Konrad A, et al. Outcomes
433 Associated With Cardiogenic Shock in Takotsubo Syndrome. *Circulation*. 2019;139(3):413-5.
- 434 6. Ong GJ, Girolamo O, Stansborough J, Nguyen TH, Horowitz JD. Incidence and
435 clinical/laboratory correlates of early hypotension in takotsubo syndrome. *ESC Heart Failure*.
436 2021;8(3):2009-15.
- 437 7. Chong CR, Neil CJ, Nguyen TH, Stansborough J, Law GW, Singh K, et al. Dissociation between
438 severity of takotsubo cardiomyopathy and presentation with shock or hypotension. *Clinical*
439 *cardiology*. 2013;36(7):401-6.
- 440 8. Abdelmoneim SS, Mankad SV, Bernier M, Dhoble A, Hagen ME, Ness SA, et al. Microvascular
441 function in Takotsubo cardiomyopathy with contrast echocardiography: prospective evaluation and
442 review of literature. *Journal of the American Society of Echocardiography : official publication of the*
443 *American Society of Echocardiography*. 2009;22(11):1249-55.
- 444 9. Rodríguez LO, Fernández RG, Luis JJ, González AP. Tako-tsubo syndrome: atypical nuclear
445 medicine findings. *World journal of nuclear medicine*. 2012;11(1):35-8.
- 446 10. De Caterina AR, Leone AM, Galiuto L, Basile E, Fedele E, Paraggio L, et al. Angiographic
447 assessment of myocardial perfusion in Tako-Tsubo syndrome. *Int J Cardiol*. 2013;168(5):4717-22.
- 448 11. Beltrame JF. Defining the coronary slow flow phenomenon. *Circulation journal : official*
449 *journal of the Japanese Circulation Society*. 2012;76(4):818-20.
- 450 12. Jaffe R, Charron T, Puley G, Dick A, Strauss BH. Microvascular Obstruction and the No-Reflow
451 Phenomenon After Percutaneous Coronary Intervention. *Circulation*. 2008;117(24):3152-6.
- 452 13. Beltrame JF, Limaye SB, Horowitz JD. The coronary slow flow phenomenon--a new coronary
453 microvascular disorder. *Cardiology*. 2002;97(4):197-202.
- 454 14. Imam H, Nguyen TH, Stafford I, Liu S, Heresztyn T, Chirkov YY, et al. Impairment of platelet
455 NO signalling in coronary artery spasm: role of hydrogen sulphide. *British journal of pharmacology*.
456 2021;178(7):1639-50.
- 457 15. Lipowsky HH, Gao L, Lescanic A. Shedding of the endothelial glycocalyx in arterioles,
458 capillaries, and venules and its effect on capillary hemodynamics during inflammation. *American*
459 *journal of physiology Heart and circulatory physiology*. 2011;301(6):H2235-45.
- 460 16. Chong CR, Chan WP, Nguyen TH, Liu S, Procter NE, Ngo DT, et al. Thioredoxin-interacting
461 protein: pathophysiology and emerging pharmacotherapeutics in cardiovascular disease and
462 diabetes. *Cardiovascular drugs and therapy*. 2014;28(4):347-60.
- 463 17. Curry FE, Adamson RH. Endothelial glycocalyx: permeability barrier and mechanosensor. *Ann*
464 *Biomed Eng*. 2012;40(4):828-39.
- 465 18. Nguyen TH, Liu S, Ong GJ, Stafford I, Frenneaux MP, Horowitz JD. Glycocalyx shedding is
466 markedly increased during the acute phase of Takotsubo cardiomyopathy. *Int J Cardiol*.
467 2017;243:296-9.

- 468 19. Surikow SY, Nguyen TH, Stafford I, Chapman M, Chacko S, Singh K, et al. Nitrosative Stress as
469 a Modulator of Inflammatory Change in a Model of Takotsubo Syndrome. *JACC: Basic to*
470 *Translational Science*. 2018;3(2):213-26.
- 471 20. Wilson HM, Cheyne L, Brown PAJ, Kerr K, Hannah A, Srinivasan J, et al. Characterization of
472 the Myocardial Inflammatory Response in Acute Stress-Induced (Takotsubo) Cardiomyopathy. *JACC*
473 *Basic Transl Sci*. 2018;3(6):766-78.
- 474 21. Girolamo OC, Surikow SY, Ong G-J, Nguyen TH, Kucia AM, Chirkov YY, et al. TakoTsubo
475 Syndrome: First an Acute Coronary Vasculitis and Then Prolonged Myocarditis? *RCM*. 2022;23(5).
- 476 22. Förstermann U. Nitric oxide and oxidative stress in vascular disease. *Pflugers Archiv* :
477 *European journal of physiology*. 2010;459(6):923-39.
- 478 23. Nguyen T, Neil CJ, Sverdlov AL, Ngo D, Chan WP, Heresztyn T, et al. Enhanced NO Signaling in
479 Patients with Takotsubo Cardiomyopathy: Short-Term Pain, Long-Term Gain? *Cardiovasc Drugs Ther*.
480 2013;27(6):541-7.
- 481 24. Chirkov YY, Holmes AS, Chirkova LP, Horowitz JD. Nitrate resistance in platelets from
482 patients with stable angina pectoris. *Circulation*. 1999;100(2):129-34.
- 483 25. Gibson CM, Cannon CP, Daley WL, Dodge JT, Alexander B, Marble SJ, et al. TIMI Frame Count.
484 *Circulation*. 1996;93(5):879-88.
- 485 26. Neil C, Nguyen T, Kucia A, Crouch B, Sverdlov A, Chirkov Y, et al. Slowly resolving global
486 myocardial inflammation/oedema in Tako-Tsubo cardiomyopathy: evidence from T2-weighted
487 cardiac MRI. *Heart (British Cardiac Society)*. 2012;98(17):1278-84.
- 488 27. Del Grande E, Taylor A. Quality of life in South Australia as measured by SF-36: population
489 norms for 2002, trends from 1994 to 2002 and impact of chronic diseases and health risk factors on
490 quality of life. In: *Population Research and Outcome Studies Unit DoHSSA, editor. South Australia:*
491 *Department of Human Services South Australia; 2004.*
- 492 28. Sato H, Tateishi H, Uchida T. Takotsubo-type cardiomyopathy due to multivessel spasm:
493 Kodama K, Haze K, Hon M, Clinical aspect of myocardial injury: from ischaemia to heart failure (in
494 Japanese Tokyo: Kagakuhyouronsya Co, 1990: 56–64. 1990.
- 495 29. Yasue H, Nakagawa H, Itoh T, Harada E, Mizuno Y. Coronary artery spasm—clinical features,
496 diagnosis, pathogenesis, and treatment. *Journal of cardiology*. 2008;51(1):2-17.
- 497 30. Nakayama N, Kaikita K, Fukunaga T, Matsuzawa Y, Sato K, Horio E, et al. Clinical Features and
498 Prognosis of Patients With Coronary Spasm–Induced Non–ST-Segment Elevation Acute Coronary
499 Syndrome. *Journal of the American Heart Association*.3(3):e000795.
- 500 31. Pelliccia F, Sinagra G, Elliott P, Parodi G, Basso C, Camici PG. Takotsubo is not a
501 cardiomyopathy. *International Journal of Cardiology*. 2018;254:250-3.
- 502 32. Gregg DE. Effect of Coronary Perfusion Pressure or Coronary Flow on Oxygen Usage of the
503 Myocardium. *Circ Res*. 1963;13:497-500.
- 504 33. Campbell LB, Gooden BA, Horowitz JD. Cardiovascular responses to partial and total
505 immersion in man. *The Journal of physiology*. 1969;202(1):239-50.
- 506 34. Choi B, Crouzet C, Lau WL, Cribbs DH, Fisher MJ. Cerebral Blood Flow in Chronic Kidney
507 Disease. *Journal of stroke and cerebrovascular diseases : the official journal of National Stroke*
508 *Association*. 2021;30(9):105702.
- 509 35. Paur H, Wright PT, Sikkil MB, Tranter MH, Mansfield C, O'Gara P, et al. High levels of
510 circulating epinephrine trigger apical cardiodepression in a beta2-adrenergic receptor/Gi-dependent
511 manner: a new model of Takotsubo cardiomyopathy. *Circulation*. 2012;126(6):697-706.
- 512 36. Sterin-Borda L, Genaro A, Perez Leiros C, Cremaschi G, Vila Echagüe A, Borda E. Role of nitric
513 oxide in cardiac beta-adrenoceptor-inotropic response. *Cellular signalling*. 1998;10(4):253-7.
- 514 37. Montone RA, Galiuto L, Meucci MC, Del Buono MG, Vergni F, Camilli M, et al. Coronary slow
515 flow is associated with a worse clinical outcome in patients with Takotsubo syndrome. *Heart (British*
516 *Cardiac Society)*. 2020;106(12):923-30.

- 517 38. Sans-Roselló J, Fernández-Peregrina E, Duran-Cambra A, Carreras-Mora J, Sionis A, Álvarez-
518 García J, et al. Prognostic Value of Microvascular Resistance at Rest in Patients With Takotsubo
519 Syndrome. *JACC: Cardiovascular Imaging*. 2022;15(10):1784-95.
- 520 39. Horowitz John D, Nguyen Thanh H. Takotsubo Syndrome. *JACC: Cardiovascular Imaging*.
521 2022;15(10):1796-8.
- 522 40. Dong F, Yin L, Sisakian H, Hakobyan T, Jeong LS, Joshi H, et al. Takotsubo syndrome is a
523 coronary microvascular disease: experimental evidence. *European Heart Journal*. 2023:ehad274.
- 524 41. Lipowsky HH, Lescanic A. The effect of doxycycline on shedding of the glycocalyx due to
525 reactive oxygen species. *Microvascular research*. 2013;90:80-5.
- 526 42. Nieuwdorp M, van Haefen TW, Gouverneur MC, Mooij HL, van Lieshout MH, Levi M, et al.
527 Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction
528 and coagulation activation in vivo. *Diabetes*. 2006;55(2):480-6.
- 529 43. Durante W, Behnammanesh G, Peyton KJ. Effects of Sodium-Glucose Co-Transporter 2
530 Inhibitors on Vascular Cell Function and Arterial Remodeling. *International journal of molecular*
531 *sciences*. 2021;22(16).
- 532 44. Mavrogeni SI, Manginas A, Papadakis E, Douskou M, Cokkinos D, Katsiva V, et al. Coronary
533 flow evaluation by TIMI frame count and magnetic resonance flow velocity in patients with coronary
534 artery ectasia. *Journal of cardiovascular magnetic resonance : official journal of the Society for*
535 *Cardiovascular Magnetic Resonance*. 2005;7(3):545-50.
- 536 45. Galderisi M, Cicala S, Caso P, De Simone L, D'Errico A, Petrocelli A, et al. Coronary flow
537 reserve and myocardial diastolic dysfunction in arterial hypertension. *American Journal of Cardiology*.
538 2002;90(8):860-4.
- 539 46. O'Brien AT, Gil KE, Varghese J, Simonetti OP, Zareba KM. T2 mapping in myocardial disease:
540 a comprehensive review. *Journal of Cardiovascular Magnetic Resonance*. 2022;24(1):33.

541

542 **Tables**

543 *Table 1: Patient demographics. Non-Gaussian data are shown as median (IQR).*

	Total patients (n=284)
Age (years)	68 (60-76)
Female, n (%)	268 (94%)
TTS triggered by a life-threatening physical illness, n (%)	68 (24%)
Apical TTS, n (%)	178 (63%)
Diabetes Mellitus, n (%)	41 (14%)
Hypertension, n (%)	135 (48%)
Current smoker, n (%)	36 (13%)
Hemoglobin, g/L	134 (126-142)
Plasma CRP, mg/L	9.5 (3.6-31)
Estimated GFR, mL/min	67 (60-90)
In-hospital mortality, n (%)	4 (1.4%)

544

545

546 *Table 2: Acute correlates of frame count: final iteration of backwards stepwise multiple*


547 *logistic regression analysis.*

Variable	β	p-value
Acute GLS	0.52	0.03
Plasma CRP concentration	-0.44	0.06
Estimated GFR	0.50	0.02


548

549 **Figures**

550 *Figure 1: Study flow chart*




553 *Figure 2: Association between corrected TIMI frame counts and A) estimated glomerular*
554 *filtration rate (eGFR), and B) lowest systolic blood pressure. Laboratory methodology*
555 *includes truncation of eGFR values at maximum of 90mL/min.*



556

557

558 *Figure 3: Primary analysis: association between corrected TIMI frame counts and acute left*
559 *ventricular global longitudinal strain (GLS).*



560

Patients diagnosed with TTS (n=400)

Patients (n=126) excluded as did not have acute coronary angiography, or did not have coronary angiography of sufficient image quality for assessment of coronary flow rates

medRxiv preprint doi: <https://doi.org/10.1101/2023.08.18.23294289>; this version posted August 21, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).


284 TTS patients included in the study

Primary analyses: Does acute vasculitis predict myocarditis?

- Correlation between TIMI frame count and myocardial dysfunction
 - GLS (n=91) – *primary hypothesis*. Correlation with LVEF (n=226) also performed.
- Correlation between TIMI frame count and:
 - (a) Consequence and evidence of eGC damage:
 - Lowest systolic blood pressure (n=240)
 - T2WSI score (n=79)
 - Plasma SD-1 concentration (n=38)
 - (b) Biochemical markers of extent of myocardial injury
 - Peak plasma Troponin-T concentration (n=274)
 - Peak plasma NT-proBNP concentration (n=267)
 - Plasma normetanephrine concentration (n=190)
 - (c) Platelet NO responsiveness (n=48)
 - (d) Extent of residual impairment 3 months post TTS
 - GLS (n=111)
 - SF36-PCS scores (n=68)
- Backwards stepwise multiple logistic regression: Correlates of coronary flow rates. Variables included into the analysis include lowest systolic BP, acute GLS, plasma CRP concentration, TTS trigger, eGFR and platelet NO responsiveness

Secondary analyses: Does acute vasculitis predict hypotension independent of myocarditis?

- Univariate correlation between lowest systolic BP and GLS (n=97)
- Backwards stepwise multiple logistic regression: Correlates of lowest systolic BP. Variables included into the analysis include age, pre-existing hypertension, TIMI frame count, acute GLS, and peaked plasma NT-proBNP and Troponin-T concentrations

A**B**